Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Safety and Tolerability Study of DeTIL-0255 in Adults With Advanced Malignancies

NCT05107739 is registered in ClinicalTrials.gov with Nurix Therapeutics, Inc. as lead sponsor.

NCT NCT05107739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05107739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Safety and Tolerability Study of DeTIL-0255 in Adults With Advanced Malignancies
Lead sponsor
Nurix Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
December 22, 2021
Completion date
May 9, 2023
Enrollment
5 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, endometrial cancer, platinum-resistant ovarian cancer